| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 17.2 | 3.3 |
| Net income | -53.3 | -32.0 |
| EPS (diluted, $ a share) | $-2.89 | $-3.59 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +423.8% |
|---|---|
| Operating margin | -321.6% |
10-Q filed with the SEC, NASDAQ: TNXP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tonix Pharmaceuticals Holding Corp.: key numbers
- Share price
- $2.88Close, Nov 16
- Market cap
- $56M
- Shares outstanding
- 19.43MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tonix Pharmaceuticals Holding Corp.
All →Tonix Pharmaceuticals Holding Court & Legal Update
Tonix Pharmaceuticals filed a patent infringement lawsuit against Dr. Reddy’s Laboratories in the U.S. District Court for the District of New Jersey following a Paragraph IV certification regarding TONMYA®. The filing of the complaint triggers a statutory 30-month stay of final FDA approval for Dr. Reddy’s proposed generic version of the drug. Tonix seeks to prevent generic competition until the expiration of its Orange Book-listed patents.
- Counterparty
- Dr. Reddy’s Laboratories Ltd.
- Term
- 30 months
Tonix Pharmaceuticals Holding CEO Seth Lederman Buys $20.3K of Stock
Seth Lederman, CEO, bought 5,000 shares of Tonix Pharmaceuticals Holding Corp. at $4.05 a share, worth $20.3K in total on Nov 11, 2026. Shares held after the trade: 16,005 (+45.4%).
- Value
- $20.3K
- Shares
- 5,000
- Price
- $4.05
- Role
- CEO
- Holding change
- +45.4%
- Trade date
- Nov 11, 2026
Tonix Pharmaceuticals Holding Financial Results
Tonix Pharmaceuticals reported Q3 2026 financial results, highlighted by $15 million in net sales for TONMYA, representing a 37% increase over the prior quarter. The company expanded its sales force to 150 representatives and secured major managed Medicare agreements covering an additional 30 million lives. As of September 30, 2026, the company held approximately $163 million in cash and cash equivalents.
- Term
- Q3 2026
“We delivered another strong quarter for TONMYA, with net sales up 37% over the second quarter. Total prescriptions, new prescriptions, and refills also increased. Payer access expanded to include two commercial group purchasing organization (GPO) agreements, two managed Medicare agreements, and Medicaid access in almost every state.”
Seth Lederman, M.D., President and Chief Executive Officer
“In addition to TONMYA’s growth, we are focused on our core clinical priorities. Our priorities include advancing TNX-102 SL in major depressive disorder (MDD), TNX-4800 for Lyme disease prevention, and the investigator-initiated study of TNX-1500 (mosdaprubart) to prevent kidney transplant rejection.”
Seth Lederman, M.D., President and Chief Executive Officer
Tonix Pharmaceuticals Holding Business Update
Tonix Pharmaceuticals provided preliminary operating results for the third quarter ended September 30, 2026, estimating net revenue for TONMYA between $14.0 million and $15.0 million. The company also reported an estimated cash and cash equivalents balance of approximately $162.8 million as of quarter-end.
- Term
- Q3 2026
Tonix Pharmaceuticals Holding Court & Legal Update
Tonix Pharmaceuticals received a Paragraph IV patent certification notice from Dr. Reddy’s Laboratories (DRL) regarding an Abbreviated New Drug Application (ANDA) for a generic version of TONMYA®. DRL claims that four of Tonix's Orange Book-listed patents are invalid, unenforceable, or not infringed. Tonix intends to vigorously enforce its intellectual property rights, which could trigger an automatic 30-month stay of FDA approval for the generic product.
- Counterparty
- Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc.
Tonix Pharmaceuticals Holding Business Update
Tonix Pharmaceuticals announced a new agreement with a major pharmacy benefit manager to provide coverage for TONMYA to approximately 21 million Medicare Part D beneficiaries. This expansion brings the total commercial and government payer coverage for the fibromyalgia treatment to approximately 166 million individuals, or 53% of the total U.S. population.